New recommendation
For diagnosis and differential diagnosis of the cause of hyperthyroidism
- TRAb measurement is recommended by guidelines for the treatment of patients with suspected conditions, such as symmetrical goiter, moderate to severe hyperthyroidism, and thyroid-associated ophthalmopathy.
- Grave’s disease is the most common cause of hyperthyroidism.
- Compared with other methods of measurement, serum assay is cost efficient and can avoid the exposure to radioactive iodine. [1]
Highly recommended
For the treatment of Grave’s disease
- The TRAb level is a predictor for discontinuing the autoimmune thyroid disease (ATD) therapy.
- Normal TRAb level indicates a greater chance for remission. [1]
Highly recommended
For the monitoring of gestation period in Grave’s disease (GD) patients
- For GD patients who took RAI therapy or thyroidectomy prior to pregnancy, the TRAb level should be measured during the first trimester and repeatedly measured at 18–22 weeks of gestation if the previous result was positive. [1,4]
- For GD patients receiving ATD therapy before pregnancy, the TRAb level should be promptly measured upon pregnancy identification. If the result is positive, the TRAb level should be measured again at 18-22 weeks of gestation. [1,4]
- If the TRAb level at 18–22 weeks of gestation is elevated, TRAb should be redetected in the late pregnancy period of weeks 30–34 to instruct neonatal monitoring. [1]
- If the serum TSH in the first trimester is lower than the gestation reference interval lower limit or less than 0.1 mU/L, T4/T3/TRAb/TPOAb should be concomitantly measured for the diagnosis of thyrotoxicosis. [4]
TRAb testing will benefit the clinicians in the following departments
To learn more about the features of Mindray's TRAb assay, please refer to the following article for details https://www.mindray.com/en/media-center/blogs/mindray-launches-trab-assay-for-graves-disease-diagnosis-and-management
References
[1] Ross DS, et al. Thyroid. 2016 Oct;26(10):1343-421.
[2] Polak M, et al. Best Pract Res Clin Endocrinol Metab, 2004, 18:289–302.
[3] Donnelly MA,et al. Obstet Gynecol, 2015, 125:1059–1062.
[4] Chin J Perinat Med, Aug. 2019, Vol. 22, No. 8. < 妊娠和产后甲状腺疾病诊治指南（第 2 版）>
